SF 17: Relating to the coverage of direct-acting antiviral drugs for Medicaid beneficiaries living with a chronic hepatitis C virus infection

What it does

This bill relates to coverage of direct-acting antivrial drugs for a chronic hepatitis C virus (HCV) infection under the Medicaid programs. The bill requires the department of human services (DHS) to adopt rules pursuant to Code chapter 17A, amend all Medicaid managed care contracts, and submit any Medicaid state plan amendments to the centers for Medicare and Medicaid services of the United States department of health and human services (CMS) for approval, as necessary, to require that direct-acting antiviral drugs that are approved by the United States food and drug administration (FDA) for the treatment of chronic HCV-infected patients as a medically accepted indication are a covered outpatient drug under the Medicaid program, and shall be covered consistently for Medicaid beneficiaries under both the fee-for-service and managed care methodologies in accordance with the Medicaid state plan.

Senate subcommittee · named January 17, 2019

• Sen. Mark Costello (R) · mark.costello@legis.iowa.gov
• Sen. Joe Bolkcom (D)
• Sen. Thomas A. Greene (R)

Lobbying · 5 for, 0 against

For: Iowa Chapter of the National Association of Pediatric Nurse Practitioners; Iowa Harm Reduction Coalition; Iowa Nurse Practitioners Society; Iowa Primary Care Association; One Iowa Action

In plain words

1. January 15, 2019Filed in the Senate and sent to the Human Resources committee
2. January 17, 2019Senate subcommittee named: Costello, Bolkcom and Greene